<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for pancreatic cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for pancreatic cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for pancreatic cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 05, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8525276">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with pancreatic cancer, both in the adjuvant setting and for advanced disease.
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with pancreatic cancer. Additional regimens may be added over time, particularly as treatment for pancreatic cancer evolves.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with pancreatic cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2475.html" rel="external">
          "Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2477.html" rel="external">
          "Treatment for potentially resectable exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2479.html" rel="external">
          "Initial chemotherapy and radiation for nonmetastatic, locally advanced, unresectable and borderline resectable, exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H8525441">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H8525449">
         <span class="h2">
          Adjuvant setting
         </span>
        </p>
        <p class="headingAnchor" id="H8525474">
         <span class="h3">
          Adjuvant gemcitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef81436" href="/z/d/graphic/81436.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3643984002">
         <span class="h3">
          Adjuvant gemcitabine plus capecitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef109104" href="/z/d/graphic/109104.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2126194506">
         <span class="h3">
          Modified FOLFIRINOX
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H8525513">
         <span class="h2">
          Locally advanced/metastatic disease
         </span>
        </p>
        <p class="headingAnchor" id="H8525538">
         <span class="h3">
          Gemcitabine monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef60330" href="/z/d/graphic/60330.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H428485721">
         <span class="h3">
          Gemcitabine plus nanoparticle albumin-bound paclitaxel (nabpaclitaxel)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89668" href="/z/d/graphic/89668.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H3139598706">
         <span class="h3">
          Gemcitabine plus capecitabine
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef103038" href="/z/d/graphic/103038.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H615559989">
         <span class="h3">
          Gemcitabine plus cisplatin
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef89633" href="/z/d/graphic/89633.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H8525617">
         <span class="h3">
          FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef79571" href="/z/d/graphic/79571.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2117393642">
         <span class="h3">
          Modified FOLFIRINOX
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef109546" href="/z/d/graphic/109546.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H936511973">
         <span class="h3">
          Modified FOLFOX6 (fluorouracil plus leucovorin and oxaliplatin)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 9
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2763016320">
         <span class="h3">
          Liposomal irinotecan and 5-FU for metastatic pancreatic cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef109026" href="/z/d/graphic/109026.html" rel="external">
          table 10
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1396323968">
         <span class="h3">
          Pembrolizumab monotherapy for microsatellite-unstable (mismatch repair-deficient) advanced cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 11
         </a>
         )
        </p>
        <p class="headingAnchor" id="H1174530377">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85690 Version 21.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
